Continued fear-mongering and lobbying for the GSK Bexsero meningococcal B vaccine product
Hi All, re aluminium-adjuvanted meningococcal B vaccination, see below my recent email to Professor Andrew Wilson, Chair of the Pharmaceutical Benefits Advisory Committee, i.e. the committee that decides whether a vaccine product will be added to the taxpayer-funded vaccine schedule in Australia. I’ve also copied in the Federal Health Minister, Greg Hunt, for what it’s worth…
Men b vax is shaping up as ‘HPV vax Mk II’, it is following the same pattern, i.e. rejected at first, the decision over-turned after extensive lobbying and fear-mongering, and then added to the schedule, working towards creating another multi-billion dollar vaccine market, for GSK and others, see for example this meningitis vaccine market report: https://www.researchne
ster.com/reports/meningitis-va ccine-market-global-demand-gro wth-analysis-opportunity-outlo ok-2023/231
Men b is already on the UK schedule. Again, it was first rejected, then frantic fear-mongering and lobbying took place, and then a new Chair took over the UK Joint Committee on Vaccination and Immunisation (JCVI), Andrew Pollard, an academic involved with the development of the then Novartis and now GSK Bexsero Men B vaccine, and next thing it’s on the schedule!
And now the fact it’s on the schedule in the UK is being justified to add it elsewhere, e.g. Australia.
International vax policy is out of control. We desperately need someone fearless with clout to see the ‘big picture’ and tackle this major global health issue.
See my email to PBAC Chair Andrew Wilson below.
For the attention of:
Professor Andrew Wilson
Chair, Pharmaceutical Benefits Advisory Committee (PBAC)
Professor Wilson, I see that fear-mongering re very rare invasive meningococcal B disease, and frenzied lobbying for the GSK Bexsero meningococcal B vaccine product, continues…
Please note that informed citizens/taxpayers are watching developments with interest in regards to the PBAC’s decisions re the taxpayer-funded vaccination schedule.
We are seeing non-expert GPs such as Bastian Seidel campaigning for the meningococcal B vaccine product in Tasmania, using his clout as President of the RACGP. I wonder if it is ethical for doctors to publicly lobby for medical products in this way? http://www.abc.net.au/ne
ws/2018-07-16/meningococcal-va ccination-program-in-tasmania- should-be-extended/9997876
Also see below an article in the conflicted Murdoch media illustrating politicians piling on support for this still ‘uncertain’ vaccine product, in this case Senator Eric Abetz.
GlaxoSmithKline must greatly appreciate all this high level product promotion…
Meanwhile informed citizens watch to see if this vaccine product for very rare invasive meningococcal B will be objectively and independently evaluated by the PBAC, particularly in light of the coercive and conflicted No Jab, No Pay law.